Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis

Bexotegrast at 320 mg was well tolerated over 12 weeks of treatment with no drug-related severe or serious adverse events; No safety concerns identified across all dose cohorts Bexotegrast at 320...

Related Keywords

United States ,Toronto ,Ontario ,Canada ,Gideon Hirshfield ,Clin Gastroenterol Hepatol ,Krisv Kowdley ,Christopher Keenan ,Terry Horner ,Linkedin ,Washington State University ,Youtube ,Elsons Floyd College Of Medicine ,Corporate Communications ,Nasdaq ,Drug Administration ,Facebook ,Liver Institute ,European Medicines Agency ,Pliant Therapeutics Inc ,University Of Toronto ,Clinical Development Next ,Globenewswire Inc ,Enhanced Liver Fibrosis ,Chief Medical Officer ,Well Tolerated ,Serious Adverse ,Demonstrated Antifibrotic Activity ,Suspected Moderate ,Severe Liver Fibrosis ,Itch Numerical Rating Scale ,Liver Institute Northwest ,Development Next ,Primary Sclerosing ,Horner Chair ,Autoimmune Liver Disease ,Pliant Therapeutics ,Fast Track Designation ,Orphan Drug Designation ,Medicines Agency ,Private Securities Litigation Reform Act ,Financial Condition ,Quarterly Report ,Media Contact ,Investor Relations ,Magn Reson ,Markets ,